TROP2-targeted NK cells for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have an advanced solid tumor that has not responded to standard treatments, or for which no standard treatment exists.
- Your tumor must show moderate to high levels of a protein called TROP2 (a test on your tumor sample will check this).
- You must be able to do most of your daily activities (ECOG performance status 0 or 1).
- You must have adequate organ function (kidney, liver, heart, and lungs) as determined by blood and other tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new type of immune cell therapy combined with radiation for advanced head and neck cancer. The cells are engineered to target the TROP2 marker on cancer cells and are given after a short course of radiation to help them work better.
This trial tests a combination of two experimental treatments: special immune cells (NK cells) and a cancer-targeting drug called T-Dxd. It's for patients with breast cancer that hasn't responded to standard treatments and has spread or cannot be surgically removed.
This trial tests a new treatment made from your own immune cells (called tumor-infiltrating lymphocytes) that are genetically modified to fight cancer better. It is for people with certain advanced solid tumors that have not responded well to other treatments.
This trial tests a new treatment called Trop2 CAR-NK, which uses your own immune cells modified to attack lung cancer cells that have a protein called Trop2. It is for people with advanced non-small cell lung cancer that has not responded to standard therapies.
This early-phase study tests an antibody-drug (an ADC) that targets TROP2, given by itself and together with an anti–PD-1 medicine. It’s for people with advanced solid cancers that have not responded to standard treatments, aiming to shrink tumors and improve control of the disease.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.